Summary of China Healthcare & Pharmaceuticals 3Q25 Drug Sales Tracker Industry Overview - The report focuses on the **China healthcare and pharmaceuticals industry**, specifically analyzing drug sales data for the third quarter of 2025 (3Q25) [1][2]. Key Findings - **Overall Market Performance**: The overall drug market sales in China declined by **6.2% year-on-year (y-y)** but increased by **6% quarter-on-quarter (q-q)**, totaling **CNY 226 billion** in 3Q25 [2][1]. - **Performance of Domestic Pharma Companies**: - **Hengrui**: Sales decreased by **0.1% y-y** to **CNY 5.8 billion**. - **Sinobio**: Sales fell by **0.9% y-y** to **CNY 4.1 billion**. - **Hansoh**: Sales declined by **0.8% y-y** to **CNY 2.0 billion**. - **Qilu Pharma**: Experienced a **9% y-y decline** to **CNY 4.7 billion**. - **CSPC**: Sales dropped by **17% y-y** to **CNY 3.6 billion** [4][4]. - **Biotech Companies' Growth**: - **BeOne**: Sales increased by **20.4% y-y** to **CNY 1.5 billion**. - **Innovent**: Sales rose by **24.6% y-y** to **CNY 1.5 billion**. - **Akeso**: Notable growth of **130.1% y-y** to **CNY 156 million**. - **Remegen**: Sales grew by **54.2% y-y** to **CNY 255 million** [5][5]. - **Multinational Corporations (MNCs) Performance**: - **AstraZeneca**: Sales decreased by **4.9% y-y** to **CNY 6.1 billion**. - **Novartis**: Sales fell by **7.3% y-y**. - **Roche**: Sales declined by **13.6% y-y**. - **Pfizer**: Sales dropped by **13.9% y-y** [6][6]. - **Notable Growth in Specific Products**: - **Novo Nordisk**: Sales increased by **22.3% y-y** to **CNY 3.7 billion**, driven by **Semaglutide** sales growth of **35% y-y** to **CNY 1.3 billion**. - **Eli Lilly**: Sales of **Tirzepatide** reached **CNY 2 million** in 3Q25 [7][7]. Additional Insights - **Hengrui's Specific Products**: - **Camrelizumab**: Sales rose by **34% y-y** to **CNY 445 million**. - **Pyrotinib**: Sales remained flat at **CNY 280 million**. - **Mecapegfilgrastim**: Sales increased by **4% y-y** to **CNY 435 million** [9][9]. - **Sinobio's Product Performance**: - **Anlotinib**: Sales grew by **6% y-y** to **CNY 646 million**. - **Magnesium Isoglycyrrhizinate**: Sales increased by **7% y-y** to **CNY 682 million** [9][9]. - **CSPC's Oncology Drugs**: - **Duomeisu**: Sales surged by **91% y-y** to **CNY 40 million**. - **Jinyouli**: Sales declined by **19% y-y** to **CNY 609 million** [10][10]. - **Hansoh's Oncology Drugs**: - **Almonertinib**: Sales rose by **14% y-y** to **CNY 560 million**. - **Flumatinib**: Sales increased by **25% y-y** to **CNY 185 million** [10][10]. Conclusion - The China healthcare and pharmaceuticals market is experiencing mixed results, with domestic companies facing declines while biotech firms show significant growth. MNCs are also struggling, indicating a challenging environment for the industry overall. The data suggests potential investment opportunities in biotech companies that are outperforming their peers.

Core Insights - Merck has initiated 15 global Phase 3 clinical trials for the TROP-2 ADC drug sacituzumab tirumotecan, enrolling 15,000 patients, indicating strong confidence in this therapeutic area [1] - Blackstone's investment of $700 million in the drug's clinical development reflects a strategic partnership aimed at mitigating the high risks associated with innovative drug development [1][2] - The collaboration allows Merck to balance innovation risks while potentially reaping significant rewards if Blackstone meets sales targets [3] Financial Implications - Blackstone's return on investment hinges on achieving a global sales target of approximately $17.5 billion, assuming a 4% royalty fee, to cover its initial $700 million investment [2] - The sales performance of Gilead's TROP-2 ADC drug suggests that reaching such targets may take considerable time, as Gilead's drug generated $1.315 billion in 2024 and $1.013 billion in the first three quarters of 2025 [2] Strategic Collaboration Model - Blackstone's approach to partnering with Merck represents a shift in collaboration strategies within the pharmaceutical industry, focusing on individual pipeline projects rather than equity stakes or new company formations [6][8] - This model preserves operational autonomy for the drug company while enhancing funding efficiency, allowing for better control over research and development directions [7][8] - The collaboration reduces operational costs and avoids the complexities associated with establishing new entities, thereby accelerating the drug approval and commercialization processes [7][8]